Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study is a single arm phase II trial including 53 patients with
T2N2-3M0、T3-4N0-3M0（III-IV） head and neck squamous cell carcinoma (HNSCC) eligible for
resection, who receive neo-adjvuant Camrelizumab combined with cisplatin and Nab-paclitaxel.
This proposed study will evaluate the efficacy and safety of preoperative administration of
Camrelizumab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) who
are about to undergo surgery.